Top in hem/onc: Colorectal cancer precursors, FDA approval of Danyelza

A recent study linked poor diet quality to an increased risk for early-onset colorectal cancer precursors. It was the top story in hematology/oncology last week.

Another top story was about the FDA approval of naxitamab-gqgk (Danyelza, Y-mAbs Therapuetics) as a treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.

Read these and more top stories in hematology/oncology below:

Poor diet quality linked to increased risk for early-onset colorectal cancer precursors

A poor-quality diet appeared to be associated with an increased risk for early-onset, high-risk distal and rectal adenomas, according to study results published in Journal of the National Cancer Institute. Read more.

FDA approves Danyelza for high-risk neuroblastoma

The FDA granted accelerated approval to naxitamab-gqgk — a humanized, monoclonal antibody that targets the ganglioside GD2 — for children aged 1 year or older and adults with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow, according to the drug’s manufacturer. Read more.

Certain patients with breast cancer could avoid lymph node surgery

More than 40% of patients with lymph node involvement at breast cancer diagnosis could be spared lymph node surgery, according to study results published in Annals of Surgical Oncology. Read more.

Sickle cell disease may increase risk for COVID-19 complications, death

Patients with sickle cell disease may be at higher risk for certain COVID-19 complications and death, according to results of two studies presented at ASH Annual Meeting and Exposition. Read more.

FDA grants fast track designation to Onivyde for small cell lung cancer

The FDA granted fast track designation to irinotecan liposome injection (Onivyde, Ipsen) for the treatment of certain patients with small cell lung cancer, according to the agent’s manufacturer. Read more.